New CEO heads Regenerys commercial drive
Regenerative medicines technology business Regenerys Ltd, which recently opened offices in Cambridge UK, has appointed a big-hitting CEO to drive a fresh phase of growth.
Now at St John’s Innovation Centre as well as in Sheffield, Regenerys is offers medical logistics and services to facilitate better cosmetic outcomes in both breast cancer surgery and other cosmetic procedures.
Its new chief executive, Dr Amr Abid, was formerly head of global strategic growth for the life sciences division of GE Healthcare where he reported to the president & CEO of life sciences, a $3.7 billion GE business.
Dr Abid was a member of the executive management team and led development of the strategy for growth and development of the life sciences at GE. Prior to that he was general manager and global leader for the Cell Technologies Division at GE Healthcare.
Before his work with GE, Dr Abid was Cell Systems Division Business Leader for the EMEA region at Life Technologies, formerly Invitrogen.
Dr Abid said: “Regenerys is uniquely positioned to address the increasing needs of clinicians in field of regenerative medicine for reconstructive procedures. It is a real privilege to be invited to be chief executive of such a pioneering business and to lead the future growth and development of Regenerys.”
Chairman Dr Bill Mason said Dr Abid’s wealth of global leadership experience in the cell therapies and regenerative medicine fields would be fundamental to the shape of the company’s activities as it moved ahead to develop its adipose and skin regenerative medicine businesses and forged commercial partnerships worldwide.
Regenerys enables storage and return of the patient's own adipose tissue for lipomodelling. Its services are provided to both NHS and private healthcare providers.
Regenerys also has novel and efficacious products for skin regeneration in the treatment of burns and potentially chronic wounds (Myskin, Cryoskin and Cryospray), using autologous and allogenic approaches with skin cells (keratinocytes).
The programme serves the growing need for autologous adipose tissue banking while avoiding the need for artificial prosthetics in reconstructive surgery. Adipose tissue has an increasing number of applications in the reconstructive and cosmetic surgical areas, as well as long term potential as a source of Adipose Derived Regenerative Cells (ADRCs) that may have therapeutic uses in wound healing, amongst others.
An adipose tissue bank makes the use of this tissue practical and affordable for patient and healthcare provider alike.
Regenerys investors include New Wave Ventures from London and a group of East Anglian-based business angels.